But that's the global estimate for the entire market. It's important to highlight that it depends upon line of treatment, type of pancreatic cancer (meaning advanced or early stage) and other factors. The global pancreatic cancer market is expected to exceed $13 billion by 2023. That equates to about 150 patients every day. Just in the United States alone there are more than 56,000 Americans who are expected to be diagnosed with pancreatic cancer in 2019. Pancreatic cancer begins when abnormal cells in the pancreas grow and start to divide out of control and form a tumor. The main lead indication that Tyme is going after is 3rd line pancreatic cancer, using its cancer drug SM-88. An Unmet Medical Need For Pancreatic Cancer For instance, maybe a checkpoint inhibitor, T-cell receptor (TCR), Chimeric antigen receptor T-cell (CAR-T), or other immunology product. However, based on its mechanism of action and breaking down the mucin layer for T-cells to attack I could potentially see a combination in the future with other immunotherapies. Right now, SM-88 is being explored in monotherapy primarily. That's why to date is has shown a good safety profile in patients treated in many studies. Therefore, Tyme has a cancer drug that does a good job of eliminating cancer cells, while leaving healthy cells alone. This is an important factor, because SM-88 doesn't have a consequence on healthy cells. The best part of all, is that tyrosine uptake it not needed for healthy cells.
This triggers cell death (apoptosis) and can also signal T-cells to come attack it.
It also acts to destabilize or kill the cancer cell through oxidative stress while the mucin layer is weakened. This is just the first portion of how SM-88 works. This in essence would allow T-cells and any other type of immunotherapy to target and easily kill these weakened cancer cells. When the tyrosine gets inside it destroys the cancer's defense system, including the mucin layer. That's why I say that this type of technology acts like a Trojan Horse. Tyme has established SM-88 as a dysfunctional tyrosine that cancer cells in the body uptake without knowing that it is toxic to do so. I would prefer to say that the mucin layer acts like a shield. Specifically, tyrosine builds out the mucin layer which protects cancer cells from a patient's T-cells or immune system. What do I mean by Trojan Horse? Well, in essence cancer cells need to uptake tyrosine to build up their defenses. Think of this drug as a Trojan Horse when it comes to targeting multiple types of cancer. The mechanism of action for SM-88 is quite amazing when you think about it. Mechanism Of Action Holds Potential To Treat Cancers With Unmet Medical Need The most notable item I like about the biotech is its SM-88 product which utilizes a type of technology known as Cancer Metabolism-Based Therapies ((CMBTs)). With all the approaching catalysts, along with a decent amount of cash, I believe it's a good buy for potential long-term investment. The biotech has already shown positive preliminary data in 3rd line pancreatic cancer and in prostate cancer using its drug SM-88. That's because it has several of them that are approaching in the coming weeks/months. Tyme Technologies ( TYME) is gearing up for many catalysts in the 2nd half of 2019.
0 kommentar(er)
